Labcorp
About: Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Employees: 67,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
29% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]
13% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 87
3% more capital invested
Capital invested by funds: $17.2B [Q3] → $17.8B (+$527M) [Q4]
0.58% more ownership
Funds ownership: 92.01% [Q3] → 92.59% (+0.58%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 327 | Existing positions reduced: 326
3% less funds holding
Funds holding: 905 [Q3] → 876 (-29) [Q4]
29% less call options, than puts
Call options by funds: $48.5M | Put options by funds: $68.4M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$260
4%
upside
Avg. target
$272
9%
upside
High target
$290
16%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target | 4%upside $260 | Neutral Maintained | 10 Feb 2025 |
Barclays Jack Meehan 100% 1-year accuracy 1 / 1 met price target | 4%upside $260 | Equal-Weight Maintained | 7 Feb 2025 |
Jefferies Tycho Peterson 47% 1-year accuracy 7 / 15 met price target | 16%upside $290 | Buy Maintained | 6 Feb 2025 |
UBS Kevin Caliendo 50% 1-year accuracy 8 / 16 met price target | 14%upside $286 | Buy Maintained | 28 Jan 2025 |
Evercore ISI Group Elizabeth Anderson 51% 1-year accuracy 18 / 35 met price target | 6%upside $265 | Outperform Upgraded | 7 Jan 2025 |
Financial journalist opinion
Based on 16 articles about LH published over the past 30 days
Positive
Seeking Alpha
1 week ago
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
Positive
Zacks Investment Research
1 week ago
Why Labcorp (LH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 week ago
Are Investors Undervaluing Labcorp (LH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
1 week ago
Here's Why Labcorp (LH) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Why Labcorp (LH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
Seeking Alpha
2 weeks ago
Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions].
Positive
Benzinga
2 weeks ago
Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.
Positive
Zacks Investment Research
2 weeks ago
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Zacks Investment Research
2 weeks ago
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Positive
Zacks Investment Research
2 weeks ago
Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates
Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago.
Charts implemented using Lightweight Charts™